In collaboration with other investigators, the TSAICG has undertaken a GWAS for GTS. The GTS GWAS should help identify short genomic segments (either SNPs or CNVs) harboring susceptibility genes for GTS. Once these genes are identified, research can be initiated to elucidate the biological pathways and processes influencing the development of the GTS phenotype. These pathways will hopefully reveal cellular and molecular mechanisms previously unsuspected in GTS pathogenesis, and thus could help to develop new treatment paradigms to significantly reduce the suffering experienced by individuals with GTS and related disorders.
